MedTrace Logo

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

NCT01198860 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2025-12-15

No results posted yet for this study

Summary

Phyllanthus Urinaria - Adenosma Glutinosum - Eclipta Prostrata - Ascorbic Acid combination plus Tenofovir in treatment of acute and chronic hepatitis B. Method the combination of drugs derived from natural and artificial medicaments.

Has stronger effect on immune system, effective good against HBV replication. This is a substantial new insight into the pathogenesis of disease, with a clear path toward clinical application, or which would lead to a substantial advance and perfect in management or public health policy.

Conditions

Interventions

DRUG

CTH Chronic Hepatitis B

Drug: * Tenofovir * Phyllanthus Urinaria * Adenosma Glutinosum * Eclipta Prostrata * Ascorbic Acid

Sponsors & Collaborators

  • Nguyen Thi Trieu, MD

    lead INDIV

Principal Investigators

  • Nguyễn Thị Triệu, Dr. · Tran Minh Duc, Dr.

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01198860 on ClinicalTrials.gov